Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: GR-7


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $139 | In Stock | In Stock | |
| 5 mg | $332 | In Stock | In Stock | |
| 10 mg | $532 | In Stock | In Stock | |
| 25 mg | $863 | In Stock | In Stock | |
| 50 mg | $1,190 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $373 | In Stock | In Stock |
| Description | Gut restricted-7 (GR-7) is a potent, covalent, orally administered, gut-selective bile salt hydrolase (BSH) inhibitor with tissue specificity that localizes to the gut. Gut restricted-7 reduces BSH activity in gut bacteria and decreases levels of unconjugated bile acids in mouse feces, making it suitable for research into metabolism, inflammation, and intestinal diseases. |
| In vitro | Methods: Six human gut symbionts (3 Gram-negative: B. theta, B. fragilis, B. vulgatus; 3 Gram-positive: L. plantarum, C. perfringens, B. adolescentis). Pre-log phase bacteria were co-incubated with Gut restricted-7 (100 μM) and mixed bile acid substrate (100 μM), monitoring deglycolysis activity over 21 hours. Results: Gut restricted-7 nearly completely inhibited bile acid deconjugation activity in all 6 strains. [1] |
| In vivo | Methods: Conventional mice were administered a single oral dose of Gut restricted-7 (10 mg/kg) or a solvent control. Feces were collected 30 hours after dosing, and BSH activity and bile acid composition were measured. Results: Levels of unconjugated bile acids in feces decreased, while the proportion of conjugated bile acids increased, confirming in vivo target inhibition and alterations in the bile acid profile. [1] |
| Synonyms | GR-7 |
| Molecular Weight | 510.64 |
| Formula | C25H40FNaO6S |
| Cas No. | 2553218-46-3 |
| Smiles | O[C@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(CF)=O)C)([H])[C@@]4([C@](C[C@@H](CC4)OS(=O)([O-])=O)([H])C1)C.[Na+] |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (489.58 mM), Sonication is recommended. H2O: 100 mg/mL (195.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.79 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.